Aberrant astrocytes impair vascular reactivity in Huntington disease

Annals of Neurology

Volumn 78, Issue 2, 2015, Pages 178-192

  Hsiao, Han Yun ^a,b   Chen, Yu Chen ^a,b   Huang, Chien Hsiang ^a,c   Chen, Chiao Chi ^a   Hsu, Yi Hua ^a   Chen, Hui Mei ^a   Chiu, Feng Lan ^d   Kuo, Hung Chih ^d   Chang, Chen ^a   Chern, Yijuang ^a,b  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOGEN; DESMIN; HUNTINGTIN; MUTANT HUNTINGTIN PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; HUNTINGTON PROTEIN, MOUSE; NERVE PROTEIN; NUCLEAR PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BLOOD OXYGENATION; BLOOD VESSEL PARAMETERS; BLOOD VESSEL REACTIVITY; BRAIN PERICYTE; BRAIN VESSEL DENSITY; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BLOOD VESSEL; BRAIN; CELL CULTURE; MAGNETIC RESONANCE ANGIOGRAPHY; METABOLISM; NERVE CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PERICYTE; TRANSGENIC MOUSE; VASCULARIZATION;

ADULT; AGED; ANIMALS; ASTROCYTES; BLOOD VESSELS; BRAIN; CELLS, CULTURED; FEMALE; HUMANS; HUNTINGTON DISEASE; INDUCED PLURIPOTENT STEM CELLS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PERICYTES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84937676020     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24428     Document Type: Article

References (45)

1. Lin CY, Hsu YH, Lin MH, et al., Neurovascular abnormalities in humans and mice with Huntington's disease. Exp Neurol 2013; 250C: 20-30.
2. Ross CA, Tabrizi SJ., Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83-98.
3. Walker FO., Huntington's disease. Lancet 2007; 369: 218-228.
4. Gusella JF, Wexler NS, Conneally PM, et al., A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983; 306: 234-238.
5. Franciosi S, Ryu JK, Shim Y, et al., Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol Dis 2012; 45: 438-449.
6. Ringelstein EB, Van Eyck S, Mertens I., Evaluation of cerebral vasomotor reactivity by various vasodilating stimuli: comparison of CO2 to acetazolamide. J Cereb Blood Flow Metab 1992; 12: 162-168.
7. Lythgoe DJ, Williams SCR, Cullinane M, Markus HS., Mapping of cerebrovascular reactivity using bold magnetic resonance imaging. Magn Reson Imaging 1999; 17: 495-502.
8. Rauscher A, Sedlacik J, Barth M, et al., Noninvasive assessment of vascular architecture and function during modulated blood oxygenation using susceptibility weighted magnetic resonance imaging. Magn Reson Med 2005; 54: 87-95.
9. Sedlacik J, Kutschbach C, Rauscher A, et al., Investigation of the influence of carbon dioxide concentrations on cerebral physiology by susceptibility-weighted magnetic resonance imaging (SWI). Neuroimage 2008; 43: 36-43.
10. Winkler EA, Bell RD, Zlokovic BV., Central nervous system pericytes in health and disease. Nat Neurosci 2011; 14: 1398-1405.
11. Chen CC, Chen YC, Hsiao HY, et al., Neurovascular abnormalities in brain disorders: highlights with angiogenesis and magnetic resonance imaging studies. J Biomed Sci 2013; 20: 47.
12. Nitta T, Hata M, Gotoh S, et al., Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 2003; 161: 653-660.
13. Bonkowski D, Katyshev V, Balabanov RD, et al., The CNS microvascular pericyte: pericyte-astrocyte crosstalk in the regulation of tissue survival. Fluids Barriers CNS 2011; 8: 8.
14. Peppiatt CM, Howarth C, Mobbs P, Attwell D., Bidirectional control of CNS capillary diameter by pericytes. Nature 2006; 443: 700-704.
15. Winkler EA, Sengillo JD, Bell RD, et al., Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability. J Cereb Blood Flow Metab 2012; 32: 1841-1852.
16. Oberheim NA, Takano T, Han X, et al., Uniquely hominid features of adult human astrocytes. J Neurosci 2009; 29: 3276-3287.
17. Allaman I, Belanger M, Magistretti PJ., Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci 2011; 34: 76-87.
18. Armulik A, Abramsson A, Betsholtz C., Endothelial/pericyte interactions. Circ Res 2005; 97: 512-523.
19. Bradford J, Shin JY, Roberts M, et al., Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A 2009; 106: 22480-22485.
20. Chou SY, Weng JY, Lai HL, et al., Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J Neurosci 2008; 28: 3277-3290.
21. Hsiao HY, Chen YC, Chen HM, et al., A critical role of astrocyte-mediated nuclear factor-kappaB-dependent inflammation in Huntington's disease. Hum Mol Genet 2013; 22: 1826-1842.
22. Mangiarini L, Sathasivam K, Seller M, et al., Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
23. Markus H, Cullinane M., Severely impaired cerebrovascular reactivity predicts stroke and TIA risk in patients with carotid artery stenosis and occlusion. Brain 2001; 124: 457-467.
24. Schilling G, Becher MW, Sharp AH, et al., Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 1999; 8: 397-407.
25. Khoshnan A, Ko J, Watkin EE, et al., Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J Neurosci 2004; 24: 7999-8008.
26. Hsiao HY, Chiu FL, Chen CM, et al., Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. Hum Mol Genet 2014; 23: 4328-4344.
27. Neng L, Zhang W, Hassan A, et al., Isolation and culture of endothelial cells, pericytes and perivascular resident macrophage-like melanocytes from the young mouse ear. Nat Protoc 2013; 8: 709-720.
28. Tigges U, Welser-Alves JV, Boroujerdi A, Milner R., A novel and simple method for culturing pericytes from mouse brain. Microvasc Res 2012; 84: 74-80.
29. Lin HH, Lai SC, Chau LY., Heme oxygenase-1/carbon monoxide induces vascular endothelial growth factor expression via p38 kinase-dependent activation of Sp1. J Biol Chem 2011; 286: 3829-3838.
30. Lin CY, Lin MH, Cheung WM, et al., In vivo cerebromicrovasculatural visualization using 3D DeltaR2-based microscopy of magnetic resonance angiography (3DDeltaR2-mMRA). Neuroimage 2009; 45: 824-831.
31. Siow TY, Chen CC, Wan N, et al., In vivo evidence of increased nNOS activity in acute MPTP neurotoxicity: a functional pharmacological MRI study. Biomed Res Int 2013; 2013: 964034.
32. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z., Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
33. Chiarini A, Whitfield J, Bonafini C, et al., Amyloid-beta(25-35), an amyloid-beta(1-42) surrogate, and proinflammatory cytokines stimulate VEGF-A secretion by cultured, early passage, normoxic adult human cerebral astrocytes. J Alzheimers Dis 2010; 21: 915-926.
34. Bell RD, Winkler EA, Sagare AP, et al., Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010; 68: 409-427.
35. Harris GJ, Codori AM, Lewis RF, et al., Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999; 122 (pt 9): 1667-1678.
36. Wolf RC, Gron G, Sambataro F, et al., Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease. J Cereb Blood Flow Metab 2011; 31: 1908-1918.
37. Chen JJ, Salat DH, Rosas HD., Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease. Neuroimage 2012; 59: 1043-1051.
38. Vis JC, Nicholson LF, Faull RL, et al., Connexin expression in Huntington's diseased human brain. Cell Biol Int 1998; 22: 837-847.
39. Cepeda-Prado E, Popp S, Khan U, et al., R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures. J Neurosci 2012; 32: 6456-6467.
40. Hua J, Unschuld PG, Margolis RL, et al., Elevated arteriolar cerebral blood volume in prodromal Huntington's disease. Mov Disord 2014; 29: 396-401.
41. Brown WR, Thore CR., Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol 2011; 37: 56-74.
42. Kalaria RN., Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev 2010; 68 (suppl 2): S74-S87.
43. Huang YC, Wu YR, Tseng MY, et al., Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington's disease. PLoS One 2011; 6: e15809.
44. Cantin S, Villien M, Moreaud O, et al., Impaired cerebral vasoreactivity to CO2 in Alzheimer's disease using BOLD fMRI. Neuroimage 2011; 58: 579-587.
45. Silvestrini M, Pasqualetti P, Baruffaldi R, et al., Cerebrovascular reactivity and cognitive decline in patients with Alzheimer disease. Stroke 2006; 37: 1010-1015.